FDA Clarifies Regulatory Expectations for Software Monitoring Cardiovascular and Metabolic Parameters in Men

FDA Clarifies Regulatory Expectations for Digital Health Technologies in Remote Physiologic Monitoring

The U.S. Food and Drug Administration maintains a Digital Health Center of Excellence to coordinate policy on tools that collect physiologic data outside clinical settings [1]. Guidance issued on December 22, 2023 spells out how sponsors should document technology performance and data practices during investigations [2]. A separate document from September 28, 2022 sets the risk-based criteria that determine when software for such monitoring counts as a regulated device [3]. These materials consolidate the agency's expectations for validation and oversight of digital health technologies used for remote physiologic monitoring.

What this means

The documents describe the FDA's current thinking on evidence standards for digital health technologies used in remote physiologic monitoring. They outline expectations around technology descriptions, usability assessments, and data reliability in clinical investigations. Manufacturers and researchers receive more detail on compliance pathways under existing risk-based rules.

Key takeaways

• FDA maintains a dedicated Digital Health Center of Excellence to advance regulatory approaches for technologies including remote physiologic monitoring [1].
• Sponsors using DHTs for remote data acquisition must describe the technology, its operational characteristics, and how it measures the clinical characteristic of interest [2].
• Recommendations call for evaluation of DHT performance, participant usability, and data integrity throughout the lifecycle of clinical investigations [2].
• FDA applies a risk-based regulatory policy to software functions including those used for physiologic monitoring [3].
• Mobile medical apps that transform a mobile platform into a regulated medical device are subject to FDA oversight. General wellness and administrative software functions are not regulated as devices [3].

FDA Digital Health Center of Excellence

The center coordinates cross-agency efforts on digital health policy, guidance development, and stakeholder engagement. It functions as the primary hub for the agency's regulatory priorities in areas such as remote physiologic monitoring [1].

Guidance on Remote Data Acquisition

The FDA issued its guidance on digital health technologies for remote data acquisition in clinical investigations on December 22, 2023. Sponsors need to supply information on how the tool operates and links to the physiologic measure it tracks. The document also directs attention to performance evaluation, participant experience, and data handling across the study [2].

Risk-Based Policy for Software Functions

FDA first outlined its policy for device software functions and mobile medical applications on September 28, 2022. Officials examine intended use and associated risks to decide regulatory status. Software that performs medical functions tied to monitoring falls under oversight in many cases. Software limited to general wellness stays outside device regulation [3].

Data Integrity and Usability Considerations

Guidance documents stress documentation of how remote technologies collect and preserve data integrity. Sponsors incorporate participant feedback on device usability into their evidence packages. Cybersecurity receives mention as a factor although the materials defer to separate federal standards for detailed requirements [2].

Limitations

FDA guidance documents are not legally binding and represent current thinking that may be updated. Recommendations focus on clinical investigations and device software. They do not address CMS reimbursement for remote physiologic monitoring services. Rapid technological evolution in wearables and AI-driven monitoring may outpace guidance refresh cycles. Guidance does not constitute comprehensive cybersecurity or privacy requirements under HIPAA or other statutes.

FAQ

What validation and evidentiary standards must DHTs meet for remote physiologic data collection according to FDA?
Sponsors must describe the technology and supply evidence of its performance, usability, and ability to produce reliable data on the clinical measure of interest.

How does the updated guidance differentiate between regulated medical devices and non-regulated wellness applications in RPM?
The agency uses a risk-based approach that examines intended use. Software that turns a platform into a regulated device falls under oversight, while general wellness functions do not.

What considerations for data integrity, usability, and cybersecurity are highlighted for remote monitoring technologies?
Documents call for evaluation of data integrity and participant usability across the study lifecycle. They note cybersecurity as a consideration but defer to other federal requirements for full standards.

How does this FDA update align with broader use of digital tools in decentralized clinical trials and telehealth?
The guidance supports responsible innovation in remote monitoring to aid decentralized trials. It provides practical compliance steps for technologies that expand access to physiologic data collection.

Sources / References

[1] Digital Health Center of Excellence. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/digital-health-center-excellence

[2] Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations

[3] Policy for Device Software Functions and Mobile Medical Applications. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications